FILE 'HOME' ENTERED AT 14:20:55 ON 08 MAR 2006

=> file reg

Uploading C:\Program Files\Stnexp\Queries\10531237.str

chain nodes : 25 26 27 28 ring nodes : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 chain bonds : 2-26 7-20 13-19 15-25 26-27 26-28 ring bonds : 1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 11-12 11-16 12-13 14-15 15-16 17-18 17-21 17-24 18-19 19-20 20-21 21-22 22-23 23-24 exact/norm bonds : 17-18 17-21 17-24 18-19 19-20 20-21 21-22 22-23 23-24 26-27 26-28 exact bonds : 2-26 7-20 13-19 15-25 normalized bonds : 1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16 isolated ring systems : containing 1 : 11 : 17 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS

STRUCTURE UPLOADED

page

L1

=> d l1

L1 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

L3 1 SEA SSS FUL L1

=> file ca

=> s 13

L4 1 L3

=> d ibib abs fhitstr

L4 ANSMER 1 OF 1 CA COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 141:23527 CA
TITLE: Preparation of quinolinyl pyrrolopyrazoles as
TOP-8 signal transduction inhibitors
Beight, Douglas Wade; Sawyer, Jason Scott; Yingling,
Jonathan Michael Jonathan Michael
Bli Lilly and Company, USA
PCT Int. Appl., 24 pp.
CODEN: PIXXD2
Patent PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION: DATE APPLICATION NO. PATENT NO. KIN DATE MO 2004048382 A1 20040610 O 2003-US32747 20031110
W: AE, AG, AL, AM, AT, AU, AZ, BB, BB, BB, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, PI, GB, GD, EC, GR, GM, HR, HU, BD, IL, IN, 16, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, 22, -40, MS, MK, MM, MK, KZ, NI, NO, NZ, OM, PG, PH, LPT, RO, RU, SC, SD, SE, SG, KS, SL, ST, TJ, TH, TR, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZM, BM, KG, KZ, ND, RU, ST, ST, ST, LS, TZ, UG, ZM, ZM, AM, AZ, BY, KG, KZ, ND, RU, TJ, TH, AT, BB, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CP, CG, C1, CM, GA, GN, GQ, GM, ML, NR, NE, SN, TD, TG

CA 2501322 AA 20040610 CA 2003-2501322 20031110
AU 2003291643 A1 20040618 AU 2003-291643 20031110
BR 2003015337 A 20050816 BR 2003-153137 20031110
EF 1565471 A1 20050824 EF 2003-758371 20031110
R: AT, BE, CH, DE, DK, EE, FR, GB, GR, IT, LIT, LU, NL, SE, MC, PT,
1E, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2006040983 A1 20060223 US 2005-531237 20050413
NO 20050303045 A 20050621 NO 2005-3045 20050613
PRIORITY APPLN. INFO.:
US 2002-428893P P 20021122 WO 2003-US32747 W 20031110

ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN (Continued)

2

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN (Continued)

The title compds. I and II, useful in treating cancer in a patient, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-4-methylquinoline and Me 6-methylpyridine-2-carboxylate (prepns. given), was given. The compds. I and II inhibit the TOF-6 type I receptor kinase domain with IC50 of <20 µM, while exhibiting less toxicity in vivo than structurally related compds. as disclosed in PCT/USO2/11884. The pharmaceutical composition comprising the compound

Claimed.
700874-72-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological atudy); PREP (Preparation); USES (Uses)
(preparation of quinolinyl pyrrolopyrazoles as TGF-β signal transduction inhibitors)
700874-72-2 CA
6-Quinolinecarboxamide, 4-[S,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

=> file marpat

=> s l1 full

FULL SEARCH INITIATED 14:21:44 FILE 'MARPAT'

FULL SCREEN SEARCH COMPLETED - 86 TO ITERATE

100.0% PROCESSED 86 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L5 1 SEA SSS FUL L1

=> d ibib abs fqhit

```
L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 138:4598 MARPAT
TITLE: Preparation of substituted
5,6-dihydro-4H-pyrrolo[1,2-
5,6-dihydro-4H-pyrrolo[1,2-
5,6-dihydro-4H-pyrrolo[1,2-
5] bypyraxoles as TGP-B signal transduction inhibitors
INVENTOR(S): Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paols; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent;
                                                                                                                                                                                                                                                                                                                    Mong-yu; Liao, Junkai, Mcmillen, Milliam Thomas; Miller, Shawn Christopher; Mort, Nicoles Anthony; Yingling, Jonethan Michael; Smith, Edward C. R. Bli Lilly and Company, USA; et al. PCT Int. Appl., 305 pp. CODEN: PIXXD2 Patent Rights 1 PCT Description of the PCT Description 
      PATENT ASSIGNEE(S):
SOURCE:
      DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                                                     PATENT NO. KIND DATE APPLICATION NO. DATE

MD 2002094833 A1 20021128 W0 2002-US11884 20020513

M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CG, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, 1D, IL, IN, IE, JP, KE, KG, KP, KR, KZ, LC, LK, LL, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PT, RO, RU, SD, SE, GG, SI, SK, SL, TJ, TM, TN, TR, TT, CU, UA, UG, US, UZ, VN, YU, ZA, ZM, ZM

RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, FT, SE, TR, BP, BJ, CF, CO, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TG

CA 2446820 AA 20021128 CA 2002-2446820 20020513

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NC, SE, MC, FT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2002009939 A 20040330 CR 2002-9939 20020513

CN 1511157 A 20040707 CN 2002-810508 20020513

JP 2004535404 T2 2004125 JP 2002-591506 20020513

ZA 20031008546 A 20050131 ZA 2003-8546 20031031

US 2004106604 A1 20046603 US 2003-477111 20031106

NO 20031005193 A 20031121 NO 2003-29393 20031121

NO 20031005193 A 20031121 NO 2003-29393 20031121

RITY APPLN. INFO::
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           APPLICATION NO. DATE
                                                                                                                                                                                                                                                                                        KIND
                                                                                                                                                                                                                                                                                                                                                             DATE
US 2004106604
NO 2003005193
PRIORITY APPLN. INFO.:
   GI
```

L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN

- 346-4 348-2

H₂C CH₂ G39

claim 1 or N-oxides and pharmaceutically acceptable salts, esters and prodrugs

REFERENCE COUNT: THERE ARE 13 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN (Continued)

Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine, pyridine, noxide, quinazoline, etc.; p = 1-8; R3 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared


instance, 1-[[2-(6-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]amino]pyrrolidin-2-one (preparation given) was treated NaW in DMF at 80-85° for 18 h to afford II in 54° yield. Selected compds. of the invention had ICSO < 20.00 μ M for the TGF- β type I receptor.


- 284

=> file reg

= :

Uploading C:\Program Files\Stnexp\Queries\237.str





chain nodes : 11 20 21 ring nodes :

1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19

chain bonds :

2-20 7-15 11-14 20-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 12-13 12-16 12-19 13-14 14-15 15-16 16-17 17-18 18-19

exact/norm bonds :

11-14 12-13 12-16 12-19 13-14 14-15 15-16 16-17 17-18 18-19 20-21

exact bonds :

2-20 7-15

normalized bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10

isolated ring systems :

containing 1 : 12 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS 21:CLASS

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6

STR

Structure attributes must be viewed using STN Express query preparation.

=> s 16 full L8 14 SEA SSS FUL L6

=> file ca

=> s 18 L9 2 L8

=> d ibib abs fhitstr 1-2

L9 ANSMER 1 OF 2 CA COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:
TITLE: 141:23527 CA quinolinyl pyrrolopyrazoles as TOF-8 eignal transduction inhibitore
Beight, Douglas Wade; Sawyer, Jason Scott; Yingling, Jonathan Michael
PATENT ASSIGNEE(S): Eli Lilly and Company, USA PCT Int. Appl., 24 pp. CODEN: PIXXD2
PATENT INFORMATION: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: DATE APPLICATION NO. PATENT NO. KIND MO 2004048382 A1 20040610 MO 2003-US32747 20001110
W: A8, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DB, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GB, GH, GM, HR, HU, ID, IL, IM, IS, JP, KE, KG, RP, KE, KZ, LC, LK, LK, LK, LT, LU, LV, MA, MD, MG, MK, NN, MN, MX, MZ, NI, MO, NZ, ON, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZM, BY, KG, KG, KG, MS, LS, TZ, UG, ZM, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, PR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CP, CG, CI, CM, QA, GN, GQ, GM, ML, MR, NE, SN, TD, TO CA 2501322 AA 20040610 CA 2003-2501322 20031110 AU 2003291643 A1 20040618 AU 2003-2501322 20031110 BR 2003015337 A 20050816 BR 2003-15337 20031110 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, 1E, SI, LT, LV, PI, RO, MX, CY, AL, TR, BC, CZ, EE, NU, SK US 200604093 A1 20060223 US 2005-531237 20050413 NO 200503045 A 20050621 NO 2005-3045 20050612 PRIORITY APPLN. INFO.:

GI

ANSWER 1 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued)

REPERENCE COUNT:

PORMAT

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

WO 2003-US32747

W 20031110

L9 ANSWER 1 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued)

The title compds. I and II, useful in treating cancer in a patient, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-4-methylquinoline and Me 6-methylpyridine-2-carboxylate (prepns. given), was given. The compds. I and II inhibit the TOF-6 type I receptor kinase domain with ICSO of <20 µM, while exhibiting less toxicity in vivo than structurally related compds. as disclosed in PCT/USO2/11884. The pharmaceutical composition comprising the compound

claimed.
700874-72-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological atudy); PREP (Preparation); USES
(Uses)

(Uses)
 (preparation of quinolinyl pyrrolopyrazoles as TGF-β signal
 transduction inhibitors)
700874-72-2 CA
6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4Hpyrrolo(1,2-b)pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 2 OF 2 CA COPYRIGHT 2006 ACS ON STN ACCESSION NUMBER: 138:4598 CA TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2"

2-blpyrazoles as TGP-β signal transduction inhibitors Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paole; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; INVENTOR (S) : Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony; Yingling, Jonathan Michael; Smith, Edward C. R. Eli Lilly and Company, USA; et al. PCT Int. Appl., 305 pp. CODEN: PIXXD2 Patent English

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

				••••															
	PA'	TENT	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.			ATE		
	WO	2002	10948	33		A1		2002	1128		WO 2	002-	US11	884		2	0020	513	
		W:	AR,	AG.	AL.	AM.	AT.	AU.	AZ.	BA.	88.	BG.	BR.	BY.	BZ.	CA.	CH.	CN.	
			co.	CR.	CU.	CZ.	DE.	DK.	DM.	DZ.	EC.	EE.	ES.	PI.	GB.	GD.	GE,	GH.	
																	LK.		
																	OM.		
																	TT.		
									ZA.				,	,	,	,	٠.,		
		RW:	GH,										183.	ZM.	2W.	AT.	BR.	CH	
																	SE.		
																	TD,		
	CA	2446																	
								CA 2002-2446820 EP 2002-744115											
			AT,																
		к.							MK.					шо,	110,	54,	mc,	F1,	
	22	2000	20099													,			
	O.	1511	1157	3,		•		2004	0330		OK 2	002	9939	^		- 1	0020	213	
	TR	1911	12264	^*		~		2004	1125		UN 2	002	B102	~		-	0020	513	
	U P	2004	5354 525	•				2004	1123		JF 4	002	2312	~		- 1	0020	213	
	NZ.	5485	0085																
			10085					2005	0131		ZA 2	003-	8546			- 1	0031	031	
			10051					2003	1121								0031		
110	RIT	r API	PLN.	INFO	. :						US 2	001-	2934	54P		P 2	0010	524	
											MU 2	002-	US11	854		. 2	0020	213	

OTHER SOURCE(S): MARPAT 138:4598

L9 ANSWER 2 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued) L9 ANSWER 2 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued)

$$(R^3)_p \xrightarrow{R^3}_{R^2} I$$

Title compds. I [Rl = Ph, pyridine, pyridine-N-cxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-cxide, naphthalene, pyridine, pyridine-N-cxide, quinazoline, etc.; P = 1-8; R1 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared

alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, 0, S] were prepared for instance, 1-[(2-(6-Brœmoquinolin-4-yl)-1-(pyridin-2-yl)-thylidene]aminolpyrrolidin-2-one (preparation given) was treated with NaH in DMP at 80-85* for 18 h to afford II in 54\$ yield. Selected compds. of the invention had ICS0 < 20.00 μM for the TGP-β type I receptor.

IT 476473-43-19, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid methyl ester RL: PAC (Pharmacological activity); RCT (Reactant); SFN (Synthetic preparation); THU (Theraputic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of (hetero)aromatic substituted 5.6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGP-β signal transduction inhibitors)
RN 476475-43-1 CA
CN 6-quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazole3-yl]-, methyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT: THIS

THERE ARE 13 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

```
10/531237
```

=> file marpat

=> s 16 full

L10 1 SEA SSS FUL L6

=> d ibib abs

L10 ANSMER 1 OF 1 MARPAT COPYRIGHT 2006 ACS ON STN ACCESSION NUMBER: 138:4598 MARPAT TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-2b]pyrazoles as TGP-β signal transduction
inhibitors
Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti,
Paols; Decollo, Todd Vincent; Godfrey, Alexander
Glenn; Goodson, Theodore, Jr.; Herron, David Kent; INVENTOR (S) Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony; Yingling, Jonathan Michael; Smith, Edward C. R. Bil Lilly and Company, USA; et al. PCT Int. Appl., 305 pp. CODEN: PIXXD2
Patent
1 PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: LANGUAGE: PAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT INFORMATION.

KIND DATE

APPLICATION NO. DATE

MOD 2002094833 A1 20021128 M0D 2002-US11884 20020513

M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BB, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, LS, LT, LU, LV, MA, MD, MG, MK, MB, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZM

RN: GH, GM, KE, LS, MM, MZ, SD, SI, SZ, LTZ, UG, ZM, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, NG, GG, GM, ML, MR, NE, SN, TD, TG

CA 2446820 AA 20021128 CA 20020513

R: AT, BE, CH, DE, DK, SS, FR, GB, GR, IT, LI, LU, NC, NL, PT, SE, TR, GB, CD, TE, SI, LT, LV, PT, RO, MK, CY, AL, TR

BR 2002009319 A 20040317 BP 2002-744115 20020513

CN 1511157 A 20040707 JP 200453404 T2 20041125 JP 2002-591506 20020513

ZZ 2003108546 A 20051013 ZA 20031121 NO 2003-5193 200310514

NO 200105193 A 20031121 NO 2003-5193 200310514

PRIORITY APPLN. INFO.: PATENT NO. APPLICATION NO. DATE

Db1 Pat 10/477/1/

L10 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN (Continued)

Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthelene, pyridine, pyridine-N-oxide, quinazoline, etc.; P = 1-8; R2 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared

FOr instance, 1-[[2-(6-Bromoquinolin-4-y1)-1-(pyridin-2-y1)ethylidene]amino]pyrrolidin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC50 < 20.00 µM for the TGP-β type I receptor.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS

13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

page

=> d his

(FILE 'HOME' ENTERED AT 14:20:55 ON 08 MAR 2006)

FILE 'REGISTRY' ENTERED AT 14:21:00 ON 08 MAR 2006

L1 STRUCTURE UPLOADED

L2 0 S L1 SAM

L3 1 S L1 FULL

FILE 'CA' ENTERED AT 14:21:24 ON 08 MAR 2006

L4 1 S L3

FILE 'MARPAT' ENTERED AT 14:21:40 ON 08 MAR 2006

L5 1 S L1 FULL

FILE 'REGISTRY' ENTERED AT 14:22:01 ON 08 MAR 2006

L6 STRUCTURE UPLOADED

L7 0 S L6 SAM

L8 14 S L6 FULL

FILE 'CA' ENTERED AT 14:23:10 ON 08 MAR 2006

L9 2 S L8

FILE 'MARPAT' ENTERED AT 14:23:53 ON 08 MAR 2006

L10 1 S L6 FULL

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:24:46 ON 08 MAR 2006